Search Within

Qin Zhou

  1. "Early Drug Development Service"
Formats
  1. Journal Article (10)
  2. Meeting Abstract (5)
Groups
  1. Biostatistics Service (15)
  2. Department of Medicine (15)
  3. Early Drug Development Service (15)
  4. Epidemiology and Biostatistics (15)
  5. Solid Tumor Oncology Division (15)
  6. GDMT, Medicine (14)

More Groups

People
  1. Alexia Iasonos (15)
  2. David Hyman (13)
  3. Rachel Grisham (13)
  4. Carol Aghajanian (12)
  5. David Spriggs (8)
  6. Gopakumar Iyer (5)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2020 (1)
  4. 2019 (1)
  5. 2018 (1)
  6. 2017 (1)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Gynecologic Oncology (3)
  3. Cancer (2)
  4. International Journal of Gynecological Cancer (2)
  5. Annals of Oncology (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (5)
  2. Elsevier Inc. (3)
  3. Lippincott Williams & Wilkins (2)
  4. Wiley Blackwell (2)
  5. American Association for Cancer Research (1)
  6. Nature Publishing Group (1)

More Publishers

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Characteristics and outcome of AKT1(E17K)-mutant breast cancer defined through AACR Project GENIE, a clinicogenomic registry
    Journal Article

    Smyth, L. M.; Zhou, Q.; Nguyen, B.; Yu, C.; Lepisto, E. M.; Arnedos, M.; Hasset, M. J.; Lenoue-Newton, M. L.; Blauvelt, N.; Dogan, S.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer
    Journal Article

    LaVigne, K.; Hyman, D. M.; Zhou, Q. C.; Iasonos, A.; Tew, W. P.; Aghajanian, C.; Makker, V.; Hensley, M. L.; Konner, J.; Grisham, R. N.; more...
    International Journal of Gynecological Cancer (2018)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • The role of systemic chemotherapy in the management of granulosa cell tumors
    Journal Article

    Meisel, J. L.; Hyman, D. M.; Jotwani, A.; Zhou, Q.; Abu-Rustum, N. R.; Iasonos, A.; Pike, M. C.; Aghajanian, C.
    Gynecologic Oncology (2015)

    Fulltext@MSK | Save
  • The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
    Journal Article

    Meisel, J. L.; Hyman, D. M.; Garg, K.; Zhou, Q.; Dao, F.; Bisogna, M.; Gao, J.; Schultz, N. D.; Grisham, R. N.; Phillips, M.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Hyman, D. M.; Aghajanian, C.
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save
  • Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save